Showing 5581-5590 of 10633 results for "".
- Dr. Sheila Fallon Friedlander Highlights Pediatric Prevention, Guidelines, and Practical Care at Maui Derm Hawaiihttps://practicaldermatology.com/news/dr-sheila-fallon-friedlander-highlights-pediatric-prevention-guidelines-and-practical-care-at-maui-derm-hawaii/2485512/Giving clinicians tools they can use “in the here and now” was the theme as Sheila Fallon Friedlander, MD, presented on pediatric dermatology in one of the opening talks at Maui Derm Hawaii 2026. Dr. Friedlander covered prevention strategies, recent guideline updates, treatment safety (esp
- Study: Mycophenolate Mofetil Effective as First-Line Option for Juvenile Localized Sclerodermahttps://practicaldermatology.com/news/study-mycophenolate-mofetil-effective-as-first-line-option-for-juvenile-localized-scleroderma/2485505/A new study comparing methotrexate (MTX) and mycophenolate mofetil (MMF) suggests MMF may offer a comparable alternative with better patient-reported tolerability outcomes. Researchers analyzed data from 114 patients (MTX [n=68
- Study Flags Gaps in Readability, Representation in Monkeypox and HIV Resourceshttps://practicaldermatology.com/news/study-flags-gaps-in-readability-representation-in-mpox-and-hiv-resources/2485494/A new study reports that critical information on monkeypox (Mpox) and HIV remains largely inaccessible to the general public due to high reading levels and inconsistent cultural representation. Researchers publishing in the <
- Doxycycline and Minocycline Show Benefit in OLP Gingival Lesionshttps://practicaldermatology.com/news/doxycycline-and-minocycline-show-benefit-in-olp-gingival-lesions/2485468/A retrospective analysis suggests doxycycline and minocycline may offer an effective systemic option for patients with inflammatory oral lichen planus (OLP) involving the gingiva who fail to respond to topical agents. Study res
- Sclerotic cGVHD Patients Show Higher Risk for Outcome Reporting Mismatchhttps://practicaldermatology.com/news/patient-reported-cgvhd-worsening-linked-to-mortality-in-sclerotic-disease/2485447/A new longitudinal cohort study published in JAMA Dermatology showed differences in frequency and importance of discordance between clinician-reported and patient-reported outcomes in cutaneous chronic graft-vs-host disease (cG
- Rapid Regrowth Tops Treatment Goals for Alopecia Areata: Surveyhttps://practicaldermatology.com/news/rapid-regrowth-tops-treatment-goals-for-alopecia-areata-survey-finds/2485419/Results from a new national survey presented at the 2026 Winter Clinical Dermatology Hawaii reveals that most US clinicians prioritize rapid and nearly complete hair regrowth, with strong satisfaction reported for Janus kinase (JAK) inhibitor therapies.
- Low-Dose Minocycline Superior in Treating Inflammatory Rosaceahttps://practicaldermatology.com/news/low-dose-minocycline-dfd-29-superior-in-treating-inflammatory-rosacea/2485398/New data presented at 2026 Winter Clinical Hawaii showed DFD-29, a modified low-dose oral minocycline 40 mg, significantly outperformed both placebo and doxycycline 40 mg in the treatment of inflammatory lesions in patients with moderate-to-severe rosacea.
- New Data Show BMI Influences Psoriasis Severity and Systemic Inflammationhttps://practicaldermatology.com/news/new-data-show-bmi-influences-psoriasis-severity-and-systemic-inflammation/2485411/Obesity and overweight status were associated with higher baseline prevalence of cardiometabolic comorbidities, psoriatic arthritis (PsA), and systemic inflammation compared to individuals with normal BMI, according to new data from a poster at 2026 Winter Clinical
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://practicaldermatology.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat
- TYK2 Inhibitor Envudeucitinib Shows Durable Skin Clearance, QoL Gains: Posterhttps://practicaldermatology.com/news/tyk2-inhibitor-envudeucitinib-shows-durable-skin-clearance-qol-gains-poster/2485378/Envudeucitinib, an investigational selective allosteric TYK2 inhibitor, showed sustained achievement of clinically meaningful treat-to-target outcomes in patients with moderate-to-severe plaque psoriasis, according to 52-week data presented at 2026 Winter Clinical